141 related articles for article (PubMed ID: 9370551)
1. Worldwide clinical safety assessment of gadoteridol injection: an update.
Runge VM; Parker JR
Eur Radiol; 1997; 7 Suppl 5():243-5. PubMed ID: 9370551
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the safety and efficacy of gadoteridol injection (a low osmolal magnetic resonance contrast agent). Clinical trials report.
DeSimone D; Morris M; Rhoda C; Lucas T; Zielonka J; Olukotun A; Carvlin M
Invest Radiol; 1991 Nov; 26 Suppl 1():S212-6; discussion S232-5. PubMed ID: 1808133
[No Abstract] [Full Text] [Related]
3. Safety of gadoteridol injection: U.S. clinical trial experience.
Olukotun AY; Parker JR; Meeks MJ; Lucas MA; Fowler DR; Lucas TR
J Magn Reson Imaging; 1995; 5(1):17-25. PubMed ID: 7696805
[TBL] [Abstract][Full Text] [Related]
4. Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases.
Yuh WT; Fisher DJ; Runge VM; Atlas SW; Harms SE; Maravilla KR; Mayr NA; Mollman JE; Price AC
AJNR Am J Neuroradiol; 1994 Jun; 15(6):1037-51. PubMed ID: 8073972
[TBL] [Abstract][Full Text] [Related]
5. Adverse reaction to intravenous gadoteridol.
Shellock FG; Hahn HP; Mink JH; Itskovich E
Radiology; 1993 Oct; 189(1):151-2. PubMed ID: 8372186
[TBL] [Abstract][Full Text] [Related]
6. Phase III clinical evaluation of gadoteridol injection: experience in pediatric neuro-oncologic MR imaging.
Debatin JF; Nadel SN; Gray L; Friedman HS; Trotter P; Hockenberger B; Oakes WJ
Pediatr Radiol; 1992; 22(2):93-8. PubMed ID: 1501959
[TBL] [Abstract][Full Text] [Related]
7. Phase II clinical trial of gadoteridol injection, a low-osmolal magnetic resonance imaging contrast agent.
Carvlin MJ; De Simone DN; Meeks MJ
Invest Radiol; 1992 Aug; 27 Suppl 1():S16-21. PubMed ID: 1506148
[TBL] [Abstract][Full Text] [Related]
8. Life-threatening anaphylactoid reaction after intravenous gadoteridol administration in a patient who had previously received gadopentetate dimeglumine.
Witte RJ; Anzai LL
AJNR Am J Neuroradiol; 1994 Mar; 15(3):523-4. PubMed ID: 8197951
[TBL] [Abstract][Full Text] [Related]
9. Dosage of gadoteridol and adverse reactions relative to gadopentetate.
Hieronim DE; Kanal E; Swanson DP
Am J Health Syst Pharm; 1995 Nov; 52(22):2556-9. PubMed ID: 8590239
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic behavior of gadoteridol injection.
McLachlan SJ; Eaton S; De Simone DN
Invest Radiol; 1992 Aug; 27 Suppl 1():S12-5. PubMed ID: 1506147
[TBL] [Abstract][Full Text] [Related]
11. Patterns of use, effectiveness and safety of gadolinium contrast agents: a European prospective cross-sectional multicentre observational study.
Jakobsen JÅ; Quattrocchi CC; Müller FHH; Outteryck O; Alcázar A; Reith W; Fraga P; Panebianco V; Sampedro A; Pietura R
BMC Med Imaging; 2021 Apr; 21(1):74. PubMed ID: 33879075
[TBL] [Abstract][Full Text] [Related]
12. Prospective Multicenter Study of the Safety of Gadoteridol in 6163 Patients.
Cho SB; Lee AL; Chang HW; Kim KA; Yoo WJ; Yeom JA; Rho MH; Kim SJ; Lim YJ; Han M
J Magn Reson Imaging; 2020 Mar; 51(3):861-868. PubMed ID: 31663202
[TBL] [Abstract][Full Text] [Related]
13. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.
Katakami N; Inaba Y; Sugata S; Tsurusaki M; Itoh T; Machida T; Tanaka H; Nakayama T; Morikawa T; Breuer J; Aitoku Y
Invest Radiol; 2011 Jul; 46(7):411-8. PubMed ID: 21467949
[TBL] [Abstract][Full Text] [Related]
14. [Artificial contrasting during magnetic resonance tomography].
Sergeev PV; Panov OV; Egorova SV; Bolotova EN; Shimanovskii NL; Akhadov TA; Sviridov NK
Vestn Rentgenol Radiol; 1997; (1):45-52. PubMed ID: 9133071
[No Abstract] [Full Text] [Related]
15. Safety and diagnostic efficacy of gadoteridol for magnetic resonance imaging of the brain and spine in children 2 years of age and younger.
Shah CC; Spampinato MV; Parmar HA; Raslan OA; Tomà P; Lin DDM; Vymazal J; Colosimo C; Enterline DS
Pediatr Radiol; 2021 Sep; 51(10):1895-1906. PubMed ID: 33950270
[TBL] [Abstract][Full Text] [Related]
16. Safety of ProHance in special populations.
Yoshikawa K; Davies A
Eur Radiol; 1997; 7 Suppl 5():246-50. PubMed ID: 9370552
[TBL] [Abstract][Full Text] [Related]
17. Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study).
Maravilla KR; Smith MP; Vymazal J; Goyal M; Herman M; Baima JJ; Babbel R; Vaneckova M; Žižka J; Colosimo C; Urbańczyk-Zawadzka M; Mechl M; Bag AK; Bastianello S; Bueltmann E; Hirai T; Frattini T; Kirchin MA; Pirovano G
AJNR Am J Neuroradiol; 2015 Jan; 36(1):14-23. PubMed ID: 25300984
[TBL] [Abstract][Full Text] [Related]
18. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
Lohrke J; Frisk AL; Frenzel T; Schöckel L; Rosenbruch M; Jost G; Lenhard DC; Sieber MA; Nischwitz V; Küppers A; Pietsch H
Invest Radiol; 2017 Jun; 52(6):324-333. PubMed ID: 28323657
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of cerebral diseases: how much contrast agent is enough? Comparison of 0.1, 0.2, and 0.3 mmol/kg gadoteridol at 0.2 T with 0.1 mmol/kg gadoteridol at 1.5 T.
Brekenfeld C; Foert E; Hundt W; Kenn W; Lodeann KP; Gehl HB
Invest Radiol; 2001 May; 36(5):266-75. PubMed ID: 11323514
[TBL] [Abstract][Full Text] [Related]
20. MRI evaluation of "solitary" brain metastases with triple-dose gadoteridol: comparison with contrast-enhanced CT and conventional-dose gadopentetate dimeglumine MRI studies in the same patients.
Kuhn MJ; Hammer GM; Swenson LC; Youssef HT; Gleason TJ
Comput Med Imaging Graph; 1994; 18(5):391-9. PubMed ID: 7954317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
